UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Information Statement
Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
MedImmune, Inc.
- --------------------------------------------------------------------------------
(NAME OF ISSUER)
Common Stock, par value $.01 per share
- --------------------------------------------------------------------------------
(TITLE OF CLASS OF SECURITIES)
584699-10-2
- --------------------------------------------------------------------------------
(CUSIP NUMBER)
April 16, 1999
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of their Statement)
-------------------------------
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ X ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
-------------------------------
Page 1 of 6 Pages
<PAGE>
SCHEDULE 13G
- ---------------------------
CUSIP No. 584699-10-2
- ---------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON: Investor AB
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a)
----
(b) X
----
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Kingdom of Sweden
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF
SHARES 3,238,000
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
-------------------------------------------------------------------
SHARED VOTING POWER
6
-------------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
3,238,000
-------------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,238,000
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
---
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.9%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
Page 2 of 6 Pages
<PAGE>
This Statement on Schedule 13G is being filed solely for the purpose of
converting the Statement on Schedule 13D filed on February 2, 1998 (the
"Schedule 13D") into a Schedule 13G for a Passive Investor under Rule 13d-1(c),
as amended by Securities and Exchange Release No. 34-39538.
ITEM 1.
(a) Name of Issuer: MedImmune, Inc.
(b) Address of Issuer's Principal Executive Offices:
35 West Watkins Mill Road, Gaithersburg, Maryland 20878
ITEM 2.
(a) Name, Address and Citizenship of Filing Person:
Investor AB ("Investor AB"), a publicly-held Swedish corporation,
whose address is S-103 32, Stockholm, Sweden, and which is engaged
in the business of the long-term holding of equity securities.
(b) Title of Class of Securities:
Common Stock
(c) CUSIP Number:
584699-10-2
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13(D)-1(B) OR
13D-2(B):
Not applicable
Page 3 of 6 Pages
<PAGE>
ITEM 4. OWNERSHIP
(a) Investor AB has record and beneficial ownership of an
aggregate of 3,238,000 shares.
(b) The 3,238,000 shares beneficially owned by Investor AB are
5.9% of the outstanding Common Stock, based upon the number
of shares of Common Stock outstanding at December 31, 1998,
as reported by the issuer in its Annual Report on Form 10-K
for the year ended December 31, 1998.
As reflected in the Schedule 13D, Investor AB initially
obtained beneficial owernship of 1,619,000 shares through
(and was deemed to share dispositive power with)
subsidiaries that were wholly-owned, directly or indirectly,
by Investor AB. Pursuant to a two-for-one stock split of the
Common Stock, Investor AB is the beneficial owner of
3,238,000 shares. Since the filing of the Schedule 13D,
Investor AB has obtained sole voting and dispositive power
over the 3,238,000 shares due to internal restructuring
among its subsidiaries.
(c) Investor AB, has sole power to vote or to direct the vote, and
to dispose or direct the disposition of, the 3,238,000 shares.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY
Not applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable
Page 4 of 6 Pages
<PAGE>
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
Page 5 of 6 Pages
<PAGE>
CUSIP No.: 584699-10-2
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete and
correct.
Investor AB
By: /s/ Henry Goss
----------------------------
Name: Henry Goss
Title: Managing Director
Page 6 of 6 Pages
<PAGE>
